Does anyone else think we are going to looking at crazy amounts of $$, when we look at targeting just 1% of sufferers to make a 10x increase in shareprice.
BOT have the only next generation medication for the condition, therefore not best in class, Sofdra is the ONLY medication in its class!!
I believe management will be secretly planning for when BOT have >20% of people with this condition wanting BOT's product, why would people not want the best medication (really the only prescription medication), i know i would.
BOT can only really skyrocket from here, it will be a happy couple of years for long termers.
Does anyone else think we are going to looking at crazy amounts...
-
- There are more pages in this discussion • 182 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.0¢ | $1.603M | 4.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 378157 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 98000 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |